Status:
COMPLETED
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
Lead Sponsor:
Copenhagen University Hospital at Herlev
Conditions:
Hematological Diseases
Hematological Malignancies
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
Eligibility Criteria
Inclusion
- Patients of 18 years or over referred to the Department of Haematology L, Herlev Hospital, with a view to 'cytostatic'? treatment of or radiotherapy for haematological malignancy
Exclusion
- Pregnant women and nursing mothers
- No informed consent from patient
- Known hyper sensitivity to bismuth or other tablet content
- Severe renal insufficiency with creatinin clearance below 25 ml/min.
- Patients receiving other treatment for protection of the mucous membrane except cryo treatment of the oral cavity (lumps of ice in the mouth)
- Other experimental treatment within past four weeks.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00892502
Start Date
May 1 2009
End Date
February 1 2013
Last Update
September 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Haematology L, Herlev Hospital, Herlev Ringvej 75
Herlev, Denmark, DK-2650